Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00980655 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
A Phase 3 study of Vaccines, Pneumococcal Conjugate Vaccine, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 251
- Enrollment target
- 20
- Study locations
NCT00980655 is a Phase 3 study of Vaccines, Pneumococcal Conjugate Vaccine that has completed, run by Pfizer. The registered enrollment target is 251 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT00980655, a Phase 3 study of Vaccines, Pneumococcal Conjugate Vaccine, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 251 participants
- Enrollment target
- 20
- Study locations
Study Summary
People who have received an allogeneic hematopoetic stem cell transplant (HSCT) are more likely than other people to get ill from a germ called Streptococcus pneumoniae. Most people who have had a stem cell transplant are offered a vaccine called 23-valent pneumococcal polysaccharide vaccine (23vPS) to help protect against this germ. The purpose of this study is to evaluate the immune response in HSCT recipients who receive a 13 valent pneumococcal vaccine (13vPnC) followed by 23vPS.
Conditions Studied
Interventions
- BIOLOGICAL 23vPS
- BIOLOGICAL 13vPnC
Study Locations (20)
Other
- Universitair Ziekenhuis Gent - Belgium
- Algemeen Ziekenhuis St.-Jan A.V. - Bruges
- Clinical University St Luc - Brussels
- Universitaire Ziekenhuizen Leuven (UZ) Gasthuisberg - Leuven
- CHU Liege - Liège
- Fakultni nemocnice Brno/Interni hematoonkologicka klinika - Bmo
- Fakultni nemocnice v Motole - Prague
- Hôpital Jean Minjoz - Besançon
- Hopital Henri Mondor - Créteil
New York
- Steven and Alexandra Cohen Children's Medical Center of New York - New Hyde Park
- Columbia University Medical Center Research Pharmacy - New York
- Columbia University Medical Center-Presbyterian Hospital Building - New York
- Columbia University/Taub Institute Irving Center for Clinical Research - New York
- New York-Presbyterian Morgan Stanley Children's Hospital - New York
- Memorial Sloan Kettering Cancer Center - New York
Kentucky
- University of Kentucky - Lexington
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Texas
- Texas Children's Hospital - Houston
Manitoba
- CancerCare Manitoba - Winnipeg
Quebec
- Hopital Maisonneuve-Rosemont - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2010-01-18 |
| Est. Completion | 2013-05-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00980655
The ClinicalTrials.gov registry entry for NCT00980655 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vaccines, Pneumococcal Conjugate Vaccine appearing as the primary indexed condition, and to 2 interventions - of which 23vPS is the first listed.
NCT00980655 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, New York, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00980655 about?
NCT00980655 is a clinical study titled "Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients". People who have received an allogeneic hematopoetic stem cell transplant (HSCT) are more likely than other people to get ill from a germ called Streptococcus pneumoniae. Most people who have had a stem cell transplant are offered a vaccine called 23-valent pneumococcal polysaccharide vaccine (23vPS)...
What is the current status of trial NCT00980655?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 251 participants. The study started on 2010-01-18. Estimated completion is 2013-05-16.
What conditions does trial NCT00980655 study?
This clinical trial studies the following conditions: Vaccines, Pneumococcal Conjugate Vaccine.
What interventions are being tested in trial NCT00980655?
The interventions under investigation include: 23vPS (BIOLOGICAL), 13vPnC (BIOLOGICAL).
Who is sponsoring clinical trial NCT00980655?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00980655 being conducted?
This trial has 20 study locations across Kentucky, New York, Pennsylvania, Texas, Manitoba. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.